Endo International PLC Forecasted to Earn Q1 2017 Earnings of $1.61 Per Share (ENDP)
Endo International PLC (NASDAQ:ENDP) – Oppenheimer Holdings issued their Q1 2017 EPS estimates for Endo International PLC in a report released on Sunday. Oppenheimer Holdings analyst R. Vanjani forecasts that the firm will post earnings of $1.61 per share for the quarter. Oppenheimer Holdings currently has a “Market Perform” rating on the stock. Oppenheimer Holdings also issued estimates for Endo International PLC’s Q3 2017 earnings at $1.10 EPS.
ENDP has been the topic of a number of other research reports. Vetr raised Endo International PLC from a “hold” rating to a “buy” rating and set a $21.95 price objective on the stock in a report on Thursday, August 25th. Mizuho reaffirmed a “buy” rating and set a $29.00 price objective on shares of Endo International PLC in a report on Monday, September 19th. Morgan Stanley set a $16.00 price objective on Endo International PLC and gave the stock a “hold” rating in a report on Thursday, September 8th. Leerink Swann reaffirmed a “market perform” rating and set a $23.00 price objective on shares of Endo International PLC in a report on Wednesday, June 29th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Endo International PLC in a report on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $39.32.
Endo International PLC (NASDAQ:ENDP) opened at 22.36 on Wednesday. The stock’s 50 day moving average price is $21.51 and its 200 day moving average price is $21.28. Endo International PLC has a 12-month low of $12.56 and a 12-month high of $72.85. The stock’s market cap is $4.98 billion.
Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings results on Monday, August 8th. The company reported $0.86 EPS for the quarter, topping the consensus estimate of $0.74 by $0.12. Endo International PLC had a positive return on equity of 15.54% and a negative net margin of 25.90%. The business had revenue of $921 million for the quarter, compared to analyst estimates of $873.50 million. During the same quarter in the previous year, the firm earned $1.08 EPS. The company’s quarterly revenue was up 25.3% compared to the same quarter last year.
Institutional investors have recently added to or reduced their stakes in the company. Meeder Asset Management Inc. bought a new stake in Endo International PLC during the first quarter worth about $139,000. LS Investment Advisors LLC raised its stake in Endo International PLC by 152.3% in the second quarter. LS Investment Advisors LLC now owns 13,661 shares of the company’s stock worth $213,000 after buying an additional 8,247 shares during the period. Icon Advisers Inc. Co. bought a new stake in Endo International PLC during the second quarter worth about $218,000. IFP Advisors Inc raised its stake in Endo International PLC by 103,542.9% in the second quarter. IFP Advisors Inc now owns 14,510 shares of the company’s stock worth $226,000 after buying an additional 14,496 shares during the period. Finally, Canada Pension Plan Investment Board raised its stake in Endo International PLC by 33.0% in the first quarter. Canada Pension Plan Investment Board now owns 9,019 shares of the company’s stock worth $254,000 after buying an additional 2,237 shares during the period. Institutional investors own 96.64% of the company’s stock.
Endo International PLC Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.